Prostaglandin E1 for diabetic neuropathy
Authors:
- 23 January 2017
- journal article
- withdrawal
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (1)
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Quantitating Overall Neuropathic Symptoms, Impairments, and Outcomes2005
- The Diabetic NeuropathiesThe Neurologist, 2004
- Polyneuropathy in the diabetic patient--update on pathogenesis and managementNephrology Dialysis Transplantation, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Assessing the quality of controlled clinical trialsBMJ, 2001
- Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: Placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcersProstaglandins, 1993
- Pathways to Diabetic Limb Amputation: Basis for PreventionDiabetes Care, 1990
- Biochemistry and Pharmacology of Prostaglandin E1: Introductory Remarks1986
- Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dogEuropean Journal of Pharmacology, 1982